The FDA has cleared Intuitive Surgical's latest robotic system for use in certain heart surgeries, marking a strategic expansion into one of healthcare's largest and most complex service lines and potentially reshaping hospital capital planning for robotics.
CONMED's latest earnings reveal a strategic pivot towards higher-growth surgical platforms, moving away from slower gastroenterology lines. While sales climbed, profitability softened, setting the stage for a crucial transition year as the market weighs the company's reset valuation against its ambitious 2026 roadmap.
While fully autonomous robotic surgeons remain on the horizon, the foundational technology and data ecosystems being built today are setting the stage for a transformative shift. Two industry giants, Intuitive Surgical and Medtronic, offer investors distinct pathways to capitalize on this evolving landscape.
The FDA has cleared Intuitive Surgical's da Vinci 5 robotic system for select complex cardiac procedures, a move that could reshape the landscape of minimally invasive heart surgery and open a significant new market for the industry leader.
Mako Mining Corp.'s updated resource estimate for its Arizona-based Moss Mine, featuring significant unencumbered silver and a streamlined path to production, is reshaping the company's investment thesis and near-term prospects.
Stryker Corporation's latest earnings report, driven by its MedSurg, Neurotechnology divisions and the Mako surgical robot, has reignited investor debate. With shares near $370 and a bullish fair value estimate of $427, analysts are weighing robust growth against a premium valuation.
The medical technology giant reported double-digit organic sales growth and robust profitability for 2025, driven by record installations of its Mako surgical robots. While projecting continued strength for 2026, management acknowledged incremental tariff pressures but expressed confidence in the company's ability to sustain margin expansion.
Amid a steep 60% annual share price decline, investment firm Chicago Capital has significantly reduced its position in PROCEPT BioRobotics, a developer of robotic systems for urological surgery, signaling a portfolio risk reassessment.
Analyst Matthew O'Brien reaffirms an Overweight rating and $420 price target for Stryker, highlighting the potential of its new Mako RPS handheld orthopedic robot to capture cost-sensitive markets and compete with rivals like Zimmer Biomet.
The medical technology giant reports double-digit organic sales growth for the fourth consecutive year, driven by its Mako robotic system and strategic leadership shifts, while navigating tariffs and a shifting competitive landscape.
Tenet Healthcare has regained complete ownership of its revenue cycle management subsidiary Conifer, buying out CommonSpirit Health's minority stake in a deal valued at nearly $2.7 billion. The move signals Tenet's renewed commitment to the business and plans for significant AI investment.
Senator James Lankford's annual oversight report details what he calls wasteful federal spending, including controversial NIH-funded projects on transgender-related animal testing and aborted fetal tissue research, reigniting debates on scientific priorities and fiscal responsibility.
Goldman Sachs CEO David Solomon, while optimistic on global markets, forecasts a deliberate deceleration in talent acquisition for 2026 as the bank sharpens its focus on operational efficiency and strategic resource allocation.
Chinese biotech firm Arctic Vision moves to create an integrated ophthalmology powerhouse by acquiring MDCO Technology's device business, combining drug and device expertise to address unmet needs in eye care.
The S&P 500 is home to market leaders, but not all its constituents are created equal. We examine one company navigating challenges and two others positioned for potential growth, providing context on their valuations and market positions.
While robust cash generation signals financial health, it doesn't guarantee stock outperformance. We analyze three cash-rich firms, highlighting one standout and two where strong cash flow masks underlying risks.
One of Ethereum's largest holders faces a potential multi-billion dollar liquidation as prices slide, prompting urgent deleveraging moves that could ripple across crypto markets.
Amidst a complex global economic backdrop, Asia's equity markets are hiding gems trading significantly below their estimated intrinsic value. We spotlight three companies—from gaming to aviation and medtech—that our cash flow analysis suggests are deeply discounted, offering potential for investors with an eye on long-term fundamentals.
Iran's Supreme Leader issues his most direct threat yet amid heightened U.S. military presence and stalled diplomacy, while internal crackdown death toll estimates soar.
Following a bold earnings surprise, UPS is betting on a strategic pivot away from low-margin deliveries. While 2026 promises a challenging start, management forecasts a powerful second-half rebound fueled by cost cuts and a focus on healthcare and SMBs.
